Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9713

Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran  

Mehrabani, Davood (Stem Cell and Transgenic Technology Research Center, Department of Pathology, Shiraz University of Medical Sciences)
Shamsdin, Seyedeh Azra (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences)
Dehghan, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences)
Safarpour, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9713-9717 More about this Journal
Abstract
Background: Colon cancer (CRC) is perhaps the second most common cause of cancer mortality. This study determined the clinical significance of serum vascular endothelial growth factor (VEGF) and serum complement 3a (C3a) levels in patients with CRC in Fars province, southern Iran. Materials and Methods: Between June 2010 and June 2012, 110 patients with CRC of both genders and different age groups were divided into 3 groups. Group A included patients who had just undergone surgery; Group B had undergone chemotherapy after surgery; and Group C had undergone chemotherapy and radiotherapy after surgery. Twenty one healthy subjects with normal colonoscopy were considered as a control group. ELISA was undertaken to determine VEGF and C3a levels before and after treatment measures. Results: The mean age of patients was $53.9{\pm}14.1$ years. Considering VEGF level, a significant decrease was visible after treatment measures in groups A and B, but not Group C. For VEGF level, the difference was not statistically significant between two genders and various age groups before and after treatment. No significant difference was found for VEGF level between patients and normal group before any treatment. Regarding C3a levels in 101 subjects, they significantly decreased after treatment measures. Before and after treatment, the difference was statistically significant between two genders, but was not statistically significant among various age groups. Conclusions: As VEGF and C3a levels were significantly lower in patients after treatment, these may be beneficial markers in assessment of CRC therapy especially in early stages.
Keywords
Colorectal cancer; VEGF; C3a; Iran;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Ahluwalia A, Jones MK, Matysiak-Budnik T, et al (2014). VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Current Pharmaceutical Design, 20, 1041-4.   DOI
2 Ahluwalia A, Jones MK, Szabo S, et al (2013). Ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem Biophys Res Commun, 437, 515-20.   DOI
3 Cetin B, Kaplan MA, Berk V,et al (2012). Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factortargeting agents. Asian Pac J Cancer Prev, 13, 1059-63.   DOI
4 Cunningham D, Atkin W, Lenz IJ, et al (2010). Colorectal cancer, Lancet, 375, 1030-47.   DOI   ScienceOn
5 Dube C, Rostom A, Lewin O, et al (2007). US Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: A systemic review prepared for the US Preventive Services Task Force. Ann Int Med, 146, 365-75.   DOI
6 Enewold L, Horner MJ, Shriver CD (2014). Socioeconomic disparities in colorectal cancer mortality in the United States, 1990-2007. J Community Health, 39, 760-6.   DOI
7 Fauci A, Rasper D, Longo D, et al (2008). Harissons Principles of Internal Medicine. Seventeenth edition. New York: McGraw Hill.
8 Ferlay J, Bray F, Pisani P, et al (2011). Cancer Incidence, Mortality and Prevalence Worldwide. GLOBOCAN, IARC Cancer Base, 5. version 2.0. http://www-dep.iarc.fr/ Accessed 10 July.
9 Greene FLPD, Fleming ID, Fritz A (2002). AJCC Cancer Staging Manual. 6th ed., New York: Springer; p. 421.
10 Habermann JK, Roblick UJ, Luke BT, et al (2006). Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131, 1020-9.   DOI   ScienceOn
11 Kanmura S, Uto H, Sato Y, et al (2010). The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol, 45, 459-67.   DOI
12 Levin B, Brooks D, Smith RA, et al (2003). Emerging technologies in screening for colorectal cancer: CT colonography. immunochemical fecal occult blood test and stool screening using molecular markers. CA Cancer J Clin, 53, 44-5.   DOI   ScienceOn
13 Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401.   과학기술학회마을   DOI
14 Kargi A, Yalcin AD, Erin N, et al (2012). Erratum to IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer. Clin Lab, 58, 1103-7.
15 Kyutoku M, Nakagami H, Koriyama H, et al (2013). Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep, 3, 3380.
16 Lieberman DA, Weiss DG, Bond JH, et al (2000). Use of colonoscopy to screen asymptomalic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med, 343, 162-8.   DOI   ScienceOn
17 Lowery JT, Horick N, Kinney AY, et al (2014). A randomized trial to increase colonoscopy screening in members of high risk families in the Colorectal Cancer Family Registry and Cancer Genetics Network. Cancer Epidemiol Biomarkers Prev, 23, 601-10.   DOI
18 Maher SG, McDowell DT, Collins BC, et al (2011). Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg, 254, 809-16.   DOI
19 Mandel JS, Church TR, Bond JH, et al (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Eng J Med, 343, 1603-7.   DOI   ScienceOn
20 Mehrabani D, Almasi-Hashiani A (2012a). Evaluation of the 5-year survival rate and demographic factors in colorectal cancer patients. Zanjan Med J, 20, 12-19.
21 Mehrabani D, Almasi-Hashiani A, Moshfeghi K, et al (2012b). Survival rate and its predictors in colorectal cancer patients, Southern Iran. Middle-East J Sci Res, 12, 1072-7.
22 Mehrabani D, Tabei SZ, Heydari ST, et al (2008). Cancer occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J, 10, 314-22.
23 Miyazaki S, Kikuchi H, Iino I, et al (2014). Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer, 135, 295-307.   DOI
24 Pignone M, Rich M, Teutsch SM, et al (2002). Screening for colorectal cancer in adults at average risk: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med, 137, 132-41.   DOI   ScienceOn
25 Qian LY, Li P, Li XR, et al (2012). Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. Asian Pac J Cancer Prev, 13, 3967-71.   과학기술학회마을   DOI
26 Saberi-Firoozi M, Kamali D, Yousefi M, et al (2007). Clinical characteristics of colorectal cancer in Southern Iran, 2005. Iran Red Crescent Med J, 9, 209-11.
27 Safarpour AR, Hosseini SV, Mehrabani D (2013). Epidemiology of Inflammatory Bowel Diseases in Iran and Asia; A Mini Review. Iran J Med Sci, 38, 140-9.
28 Talaiezadeh A, Tabesh H, Sattari A, et al (2013). Cancer incidence in southwest of Iran: First report from Khuzestan population-based cancer registry, 2002-2009. Asian Pac J Cancer Prev, 14, 7517-22.   과학기술학회마을   DOI   ScienceOn
29 Smith RA, Eschenbach AC, Wender R (2001). ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee: American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin, 51, 38-75.   DOI   ScienceOn
30 Szajewski M, Kruszewski WJ, Lakomy J (2014). VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep, 31, 125-30.
31 Wang Y, Han G, Wang K, et al (2014). Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res, 74, 716-26.   DOI
32 Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905.   DOI   ScienceOn
33 Winawer SJ, Flehinger BJ, Scholtenfeld D, et al (1993). Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst, 85, 1311-8.   DOI   ScienceOn
34 Yousefi AR, Karimi MH, Shamsdin SA, et al (2013). PD-1 Gene polymorphisms in Iranian patients with colorectal cancer. Lab Medicine, 44, 23-6.
35 Zubero MB, Arana-Arri E, Pijoan JI, et al (2014). Populationbased colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol, 4, 175.